AstraZeneca has announced a jump in sales in recent months after a surge in demand for cancer drugs, as the pharmaceutical ...

This landmark investment reflects not only America's importance but also our confidence in our innovative medicines to transform global health and power AstraZeneca's ambition to deliver $80 billion ...

Total revenue rose 11 per cent to $28bn (£12.98bn) in the first half of the year, driven by double-digit growth in Oncology ...

Revenue from oncology products made up 43 per cent of Astrazeneca's revenue in the first half of 2025, up 15 per cent year on ...

Cambridge headquartered AstraZeneca saw its UK share price rocket 328p to 11,118 and its market cap soar to £173.49 billion after a stunning set of results for the first half and second quarter of ...

Drugmaker Astrazeneca said on Tuesday that "strong growth momentum" had continued in H1, with "excellent R&D pipeline ...

Barclays today said half-year pre-tax profits rose 23% to £5.2 billion, boosted by a 28% improvement in the second quarter of ...

The AstraZeneca share price has been treading water for the past few years, but first-half results add strength to rising ...

The Anglo-Swedish pharmaceutical giant said Tuesday that for the second quarter, core earnings per share rose to $2.17 from $1.98 in the same period a year prior. Revenue increased to $14.46 billion ...

Pharmaceutical giant AstraZeneca has reported increased revenue across all its major geographic regions and increased interim profits as the listed business maintained its growth ...

AstraZeneca PLC (NASDAQ: AZN) ranks among the stocks to benefit from an onshoring boom. AstraZeneca PLC (NASDAQ:AZN) ...